Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016991 | 0.92 | PPARG (0.40) | MAPTKDM4ENPSR1GSK3AGSK3B | |
| SCHEMBL5016959 | 0.89 | HDAC1 (0.40) | GHSRMAPTPTGS2KDM4EHPGD | |
| SCHEMBL5016928 | 0.88 | HSD17B10 (0.42) | GHSRMAPTPTGS2SMN1; SMN2KDM4E | |
| SCHEMBL14365374 | 0.87 | GHSR (0.41) | GHSRMAPTPTGS2SMN1; SMN2KDM4E | |
| SCHEMBL5023079 | 0.86 | ALDH1A1 (0.44) | MAPTSMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL5016958 | 0.84 | MEN1 (0.44) | GHSRMAPTPTGS2KDM4EHPGD | |
| SCHEMBL5017118 | 0.82 | NTRK1 (0.39) | MAPTKDM4EHPGDNPSR1HSD17B10 | |
| SCHEMBL27677755 | 0.81 | LMNA (0.53) | MAPTSMN1; SMN2KDM4ELMNARAB9A | |
| SCHEMBL5017068 | 0.81 | PTGS2 (0.49) | GHSRMAPTPTGS2SMN1; SMN2LMNA | |
| SCHEMBL5022953 | 0.80 | KDM4E (0.53) | MAPTSMN1; SMN2KDM4EHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638556-B1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | EP | claimed |
| CN-100368407-C | 2-aminobenzothiazoles as CB1 receptor inverse agonists | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | CN | claimed |
| US-7297707-B2 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-11-20 | — | — | US | claimed |
| US-20070021478-A1 | Benzothiazolyl derivatives | NETTEKOVEN MATTHIAS H | 2007-01-25 | — | — | US | claimed |
| US-20040266845-A1 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. | 2004-12-30 | — | — | US | claimed |
| EP-1638556-B1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | EP | disclosed |
| CN-100368407-C | 2-aminobenzothiazoles as CB1 receptor inverse agonists | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | CN | disclosed |
| US-7297707-B2 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297707-B2 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297707-B2 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-11-20 | — | — | US | disclosed |
| US-20070021478-A1 | Benzothiazolyl derivatives | NETTEKOVEN MATTHIAS H | 2007-01-25 | — | — | US | disclosed |
| US-20070021478-A1 | Benzothiazolyl derivatives | NETTEKOVEN MATTHIAS H | 2007-01-25 | — | — | US | disclosed |
| US-20070021478-A1 | Benzothiazolyl derivatives | NETTEKOVEN MATTHIAS H | 2007-01-25 | — | — | US | disclosed |
| US-20040266845-A1 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021478-A1 | Benzothiazolyl derivatives | CNR1, CNR2, GPR119 | GHSR 143/4885MAPT 3262/4885PTGS2 2165/4885 |
| US-20040266845-A1 | Benzothiazolyl derivatives | CNR1, CNR2, GPR119 | GHSR 171/4885MAPT 3619/4885PTGS2 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.